Values First Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

Values First Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$267K	Sell	72,647 -1,589	-2%	-$5.29K	0.12%	158
2026 Q1	$228K	Buy	74,236 +2,043	+3%	+$7.89K	0.12%	155
2025 Q4	$295K	Sell	72,193 -17,022	-19%	-$84.3K	0.15%	139
2025 Q3	$435K	Sell	89,215 -1,759	-2%	-$9.24K	0.23%	114
2025 Q2	$460K	Buy	90,974 +1,011	+1%	+$4.97K	0.25%	111
2025 Q1	$481K	Buy	89,963 +188	+0.2%	+$1.37K	0.28%	100
2024 Q4	$607K	Buy	89,775 +29,552	+49%	+$199K	0.33%	82
2024 Q3	$397K	Sell	60,223 -1,540	-2%	-$11K	0.22%	108
2024 Q2	$463K	Sell	61,763 -370	-0.6%	-$3.23K	0.28%	90
2024 Q1	$619K	Buy	62,133 +2,928	+5%	+$32.6K	0.36%	77
2023 Q4	$584K	Buy	59,205 +6,140	+12%	+$43.8K	0.35%	87
2023 Q3	$406K	Sell	53,065 -361	-0.7%	-$3.6K	0.26%	106
2023 Q2	$399K	Buy	53,426 +23,137	+76%	+$162K	0.24%	109
2023 Q1	$202K	Buy	+30,289	New	+$240K	0.13%	137

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Values First Advisors's RXRX Position: Q2 2026 in Review

Values First Advisors reduced its Recursion Pharmaceuticals (RXRX) stake by 2.1% in Q2 2026, selling an estimated $5.29K and leaving 72,647 shares worth $267K. The position accounts for 0.12% of the portfolio, ranked #158.

Values First Advisors first reported a position in RXRX in Q1 2023 and has held it in 14 quarters since. The position peaked at $619K in Q1 2024. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Values First Advisors held 72,647 shares of Recursion Pharmaceuticals worth $267K as of Q2 2026.
Values First Advisors sold 1,589 Recursion Pharmaceuticals shares in Q2 2026, an estimated $5.29K.
Recursion Pharmaceuticals made up 0.12% of Values First Advisors's portfolio in Q2 2026, its #158 holding.
Values First Advisors first reported a position in Recursion Pharmaceuticals in Q1 2023 and has held it in 14 quarters since.
Values First Advisors's Recursion Pharmaceuticals position peaked at $619K in Q1 2024.
342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Values First Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.